
MT-1 · 10 mg
A synthetic copy of your own tanning hormone, α-MSH, with two amino acids changed so it lasts long enough to work. It's the original melanotan — and the only one that ever became an approved medicine. It leans on MC1R, the pigment receptor, which is why it has fewer of Melanotan II's side effects. It's also why it's slower.
Includes 10× sterile insulin syringes + 1 vial of bacteriostatic water, free with your order.
Complete your kit
For research and educational use only. Not for human or veterinary consumption.
What has been shown in human trials:
- It makes your skin produce more eumelanin — the brown-black pigment that absorbs UV. In a 2000 trial, forearm eumelanin roughly doubled one week after a 10-day course.
- It works on fair skin too. The first trial in 1991 darkened poor tanners and good tanners alike.
- Sun and MT-1 work together. In the 2004 Arizona trials, the sun-only group needed 50% more exposure for the same tan.
- The tan outlasts a natural one. It peaked 1–3 weeks after the last injection and was still present 3 weeks later; in one protocol it persisted at 11 weeks while sun-only tans had faded by 5.
- Less UV damage at the cellular level — at trial doses: 47% fewer sunburn cells in one study, 59% fewer DNA lesions (thymine dimers) in another.
What people report:
- A more even, natural-looking tan than MT-II, built gradually over weeks rather than days
- Freckles and moles darken first, before the overall skin tone moves
- Less libido and appetite effect than MT-II — the main reason people choose it
MT-1 or MT-II — which one is for you?
| MT-1 | Melanotan II | |
|---|---|---|
| Receptors | Mainly MC1R (pigment) | MC1R plus MC3R/MC4R in the brain |
| Speed | Gradual — weeks | Fast — days to two weeks |
| Depth | Moderate, even | Darker, can be patchy over freckles |
| Libido / erections | Less often reported | Common — often unexpected |
| Appetite | Little change | Often suppressed |
| Nausea | Reported, especially early | Common |
| Evidence | Several published trials; approved medicine (as an implant) | Small pilot trials; never approved |
Choose MT-1 if you want pigment with fewer of MT-II's other effects, and you're patient. Choose MT-II if speed and depth matter more to you than side effects. Both darken moles. The mole gate applies to both.
It does not tan you on its own — it amplifies the tan you get from the sun. You still need UV, and you'll respond more strongly than you're used to. Shorter sessions, not longer.
It is not sunscreen. The trials showed less UV damage in the skin, but that is not the same as protection. Keep using sunscreen and never let yourself burn.
It is slower than MT-II. If you want to be dark by next week's holiday, this isn't it.
This vial is not Scenesse. The approved medicine is a 16 mg slow-release implant, inserted by a doctor every two months for a rare light-sensitivity disease. What we supply is research-grade afamelanotide powder. Same molecule, different product, no approval for tanning anywhere.
🛑 We will not sell this to you if:
You have a lot of moles, or any personal or family history of melanoma or skin cancer. MT-1 darkens existing moles and can bring out new ones, which makes changes harder to spot — and spotting those changes is how skin cancer gets caught early. This isn't a disclaimer. We'll decline the order and suggest something else.
Also don't use it if you're pregnant or breastfeeding, under 18, or have reduced liver or kidney function. The approved medicine is not to be used in liver or kidney impairment, and there is no human pregnancy data.
Common:
- Nausea, usually within the first hour
- Facial flushing, brief
- Headache
- Tiredness on injection days
- Darkening of existing moles and freckles — expected, not a reaction
In the approved medicine's trials, nausea ran 19% against 14% on placebo and headache about 1 in 5. In the 1990s–2000s injection trials, side effects were limited to nausea, flushing and fatigue.
Less common:
- New moles (4% vs 2% on placebo in the approved-drug trials)
- Generalised darkening beyond the tan you were aiming for
- Dizziness
- Injection site redness or a small lump
Stop and see a doctor:
- Any mole that changes shape, size or colour, or a new one that looks different from the rest. Photograph your moles before you start and compare monthly. This is the important one.
- Swelling of the face, lips or throat, hives, or difficulty breathing — rare allergic reactions have been reported with the approved medicine
- Vomiting that doesn't settle
What's reassuring and what isn't: more than 1,000 patients have been on the approved implant, some for over 10 years, with no melanoma reported. That's real. But those patients use sun protection, get skin checks twice a year, and receive a pharmaceutical product. Unregulated melanotan use — mostly MT-II, some MT-I — has been linked in case reports to changing moles, new dysplastic moles and four melanomas. Causation isn't proven. We'd still rather you knew.
Draw past the line, tap out bubbles, push back to the line.
The AVERON Peptide Pen delivers 1 click = 0.01 mL. A U-100 insulin syringe delivers 1 unit = 0.01 mL. They are the same number. 20 clicks on the pen and 20 units on a syringe deliver exactly the same dose.
Maximum per injection: 100 units (1 mL)
10 mg vial + 2 mL bacteriostatic water = 5 mg/mL. Beyond the basic mix, there isn't enough reliable data at the doses people actually use for us to publish a protocol — message us on WhatsApp.
Draw past the line, tap out bubbles, push back to the line.
The AVERON Peptide Pen delivers 1 click = 0.01 mL. A U-100 insulin syringe delivers 1 unit = 0.01 mL. They are the same number. 20 clicks on the pen and 20 units on a syringe deliver exactly the same dose.
Maximum per injection: 100 units (1 mL)
We don't publish a dosing protocol for MT-1. The published tanning trials used doses far above what a research vial provides, and the lower doses circulating online have never been studied — so we won't guess one. Message us on WhatsApp and we'll tell you honestly what we know and don't know. Never run MT-1 and MT-II on the same day.
- 1× MT-1 · 10 mg
- 10× sterile insulin syringes (free)
- 1× bacteriostatic water vial (free)
- Compound Guide — printed, included free
MT-1 is the best-studied tanning peptide by a wide margin. Placebo-controlled and phase 1 injection trials ran from 1991 to 2006 at the University of Arizona and in Australia, and showed real increases in skin eumelanin and real tanning — at doses far above what research vials provide.
As afamelanotide (Scenesse), a 16 mg implant every two months, it is an approved medicine for erythropoietic protoporphyria, a rare disease where light causes burning pain: European Union in 2014 (under exceptional circumstances), the US FDA in 2019, Australia's TGA in 2020. It was also trialled with light therapy for vitiligo. It is not approved for cosmetic tanning anywhere, and the research-grade powder we supply is not the approved product. Long-term safety of self-injected MT-1 has never been studied.
Athletes: afamelanotide is not named on the WADA Prohibited List, and as an approved medicine it doesn't fall under S0 as written. Research-grade material is not the approved medicine — check with your anti-doping agency before using it.
- Levine et al., JAMA, 1991 — 10 subcutaneous injections over 12 days darkened the skin of 28 men, poor and good tanners alike; placebo did nothing
- Ugwu et al., Biopharmaceutics & Drug Disposition, 1997 — subcutaneous MT-I fully bioavailable vs IV, oral did nothing; tan peaked ~1 week after dosing
- Dorr et al., Photochemistry and Photobiology, 2000 — a 10-day course roughly doubled forearm eumelanin one week after dosing
- Dorr et al., Archives of Dermatology, 2004 — three phase 1 trials: MT-1 plus sun tanned faster and lasted longer; side effects limited to nausea and flushing
- Barnetson et al., J Invest Dermatol, 2006 — 3 × 10-day courses in 65 volunteers raised melanin density ~41% in fair skin and cut UV-induced thymine dimers by 59%
- Langendonk et al., NEJM, 2015 — two phase 3 trials (168 patients) of the 16 mg implant increased pain-free sun exposure in erythropoietic protoporphyria
- FDA, SCENESSE prescribing information, 2019 — nausea 19% vs 14%, melanocytic nevus 4% vs 2%; twice-yearly full-body skin exam recommended
- EMA, Scenesse EPAR — authorised 22 December 2014 under exceptional circumstances
- Habbema et al., Int J Dermatol, 2017 — unregulated melanotan I and II linked to changing moles and new dysplastic nevi; four melanoma case reports, causation unproven
- Böhm et al., JEADV, 2024 — afamelanotide ranks MC1R > MC3R > MC4R; >1,000 patients exposed with no melanoma reported
Every peptide batch we sell is tested by Janoshik Analytical, an independent laboratory. Every vial carries an internal AVERON batch code identifying the lot received; each lot is linked to its published Janoshik report. The report carries the manufacturer's submission/task number, not the AVERON code. Ask us or our driver which report covers your code and open it on the laboratory's own website before paying. In our own-driver zone, the team shows you the vial and the report for that batch before payment.
A lab report handed to you by a seller and a lab report you can verify yourself are not the same thing. That's why we publish ours.
View COA on JanoshikMore in Aesthetics & Tanning


Melanotan II Nasal Spray
Melanotan II in a ready-to-use metered nasal spray

GHK-Cu
Copper peptide for skin, hair and everyday support.







